Vanguard Fiduciary Trust
IMDX

Vanguard Fiduciary Trust’s Insight Molecular Diagnostics IMDX Stock Holding History

Vanguard Fiduciary Trust’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$735K Sell
124,576
-8,015
-6% -$39.6K ﹤0.01% 3139
2026
Q1 		$435K Buy
+132,591
New +$770K ﹤0.01% 3254

Other funds holding IMDX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
FOR
Family Office Research Bethesda, Maryland $267M AUM 27.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Fiduciary Trust's IMDX Position: Q2 2026 in Review

Vanguard Fiduciary Trust reduced its Insight Molecular Diagnostics (IMDX) stake by 6% in Q2 2026, selling an estimated $39.6K and leaving 124,576 shares worth $735K. The position accounts for ﹤0.01% of the portfolio, ranked #3139.

Vanguard Fiduciary Trust first reported a position in IMDX in Q1 2026 and has held it in 2 quarters since. 39 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

  • Vanguard Fiduciary Trust held 124,576 shares of Insight Molecular Diagnostics worth $735K as of Q2 2026.
  • Vanguard Fiduciary Trust sold 8,015 Insight Molecular Diagnostics shares in Q2 2026, an estimated $39.6K.
  • Insight Molecular Diagnostics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3139 holding.
  • Vanguard Fiduciary Trust first reported a position in Insight Molecular Diagnostics in Q1 2026 and has held it in 2 quarters since.
  • 39 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.